OHSU launches gene therapy trial for AMD

Article

Portland, OR-Researchers in the Casey Eye Institute at Oregon Health & Science University (OHSU) began participation in February in a gene therapy trial for patients with age-related macular degeneration (AMD).

Recent Videos
Cassandra Gorsuch, PhD, chief scientific officer at Precision
Cassandra Gorsuch, PhD, chief scientific officer at Precision
Linda Marbán, PhD, the CEO of Capricor Therapeutics
Matthew Wicklund, MD, a professor of neurology at the University of Texas Health Science Center San Antonio
Matthew Wicklund, MD, a professor of neurology at the University of Texas Health Science Center San Antonio
Renier Brentjens, MD, PhD, the chair of the department of medicine and the deputy director at Roswell Park Comprehensive Cancer Center
Renier Brentjens, MD, PhD, the chair of the department of medicine and the deputy director at Roswell Park Comprehensive Cancer Center
Renier Brentjens, MD, PhD, the chair of the department of medicine and the deputy director at Roswell Park Comprehensive Cancer Center
Renier Brentjens, MD, PhD, the chair of the department of medicine and the deputy director at Roswell Park Comprehensive Cancer Center
David-Alexandre C. Gros, MD, Eledon’s chief executive officer
Related Content
The Evolving Landscape of Gene and Cell Therapies in Parkinson Disease: Pipeline Highlights

The Evolving Landscape of Gene and Cell Therapies in Parkinson Disease: Pipeline Highlights

Isabella Ciccone, MPH;Marco Meglio;Noah Stansfield;Matt Hoffman
April 30th 2025
Article

Emerging gene and cell therapies aim to slow Parkinson disease progression. Explore clinical updates on seven promising candidates in development.

ImmunoLogic

ImmunoLogic, Episode 3: "Breaking the Brain’s Barrier: CAR T-Cells Take on Glioblastoma" With Marcela Maus, MD, PhD

Joseph A. Fraietta, PhD;Janna Minehart, MD;Marcela V. Maus, MD, PhD;Noah Stansfield;Matt Hoffman
April 8th 2025
Podcast

In Episode 3 of ImmunoLogic, Marcela Maus, MD, PhD, discussed her research on CAR-T for treating glioblastoma.

FDA Approves Abeona Therapeutics' Epidermolysis Bullosa Gene Therapy Pz-Cel

FDA Approves Abeona Therapeutics' Epidermolysis Bullosa Gene Therapy Pz-Cel

Noah Stansfield
April 29th 2025
Article

The agency's decision was based on data from the phase 3 VIITAL study (NCT04227106).

ImmunoLogic

ImmunoLogic, Episode 2: "Charting New Frontiers in CAR T-Cell Safety" With Bruce Levine, PhD

Joseph A. Fraietta, PhD;Janna Minehart, MD;Noah Stansfield;Matt Hoffman
March 11th 2025
Podcast

In Episode 2 of ImmunoLogic, Bruce Levine, PhD, discussed the current the risk-benefit-ratio for CAR-T therapy.

CGTLive®’s Weekly Rewind

CGTLive®’s Weekly Rewind – April 25, 2025

Noah Stansfield
April 25th 2025
Article

Review top news and interview highlights from the week ending April 25, 2025.

BrainChild Bio's Pediatric Brain Tumor CAR-T BCB-276 Reels in Breakthrough Therapy Designation

BrainChild Bio's Pediatric Brain Tumor CAR-T BCB-276 Reels in Breakthrough Therapy Designation

Noah Stansfield
April 25th 2025
Article

The FDA’s decision was supported by data indicating overall survival benefit for patients with brain tumors from the phase 1 BrainChild-03 clinical trial.

© 2025 MJH Life Sciences

All rights reserved.